| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| | Cenupatide Basic information |
| Product Name: | Cenupatide | | Synonyms: | Cenupatide;AC-ARG-AIB-ARG-Α(ME)PHE-NH2;Cenupatide TFA;L-Phenylalaninamide, N2-acetyl-L-arginyl-2-methylalanyl-L-arginyl-α-methyl-;Cenupatide free base;N2-Acetyl-L-arginyl-2-methylalanyl-L-arginyl-α-methyl-L-phenylalaninamide (ACI) | | CAS: | 1006388-38-0 | | MF: | C28H47N11O5 | | MW: | 617.76 | | EINECS: | | | Product Categories: | | | Mol File: | 1006388-38-0.mol |  |
| | Cenupatide Chemical Properties |
| density | 1.34±0.1 g/cm3(Predicted) | | pka | 12.99±0.46(Predicted) | | form | Solid | | color | White to off-white | | Sequence | Ac-Arg-{Aib}-Arg-{aMePhe}-NH2 |
| | Cenupatide Usage And Synthesis |
| Uses | Cenupatide (UPARANT) is a Urokinase-type plasminogen activator receptor (uPAR) inhibitor. Cenupatide has anti-angiogenic and anti-inflammatory efficacy[1]. | | References | [1] Filippo Locri, et al. UPARANT is an effective antiangiogenic agent in a mouse model of rubeosis iridis. J Mol Med (Berl). 2019, 97, 9.
[2] Cai Yuan, et al. Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. Drug Discov Today. 2021, 26, 4. DOI:10.1016/j.drudis.2021.01.016 |
| | Cenupatide Preparation Products And Raw materials |
|